Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US clearance of cerebral oximeter expanded

This article was originally published in Clinica

Executive Summary

The US FDA has expanded the range of patients who can be treated with CAS Medical Systems' Fore-Sight cerebral oximeter. The extended 510(k) clearance allows Fore-Sight to be used on all patients, including newborns weighing less than 2.5kg. The device is a near infra-red spectroscopy-based device that non-invasively and continuously detects oxygen saturation changes in brain tissue, allowing clinicians to quickly react to reverse potentially harmful events before they become critical. Fore-Sight will be used to monitor smaller neonates at risk of intra-ventricular haemorrhage, central apnoea and seizures. Branford, Connecticut-based CAS gained initial FDA clearance for the device in March 2008 (see Clinica No 1297, p 22).

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT044165

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel